Women attempting to conceive: a key clinical cohort for biomarker discovery
MELISA Institute is continuously recruiting a cohort of couples seeking a pregnancy and collecting samples for a biobank from different phases of the fertile cycle and over an ongoing pregnancy. This biorepository is key to investigate biomarkers with potential applications in prenatal medicine.

Moving toward the first clinical trial for prenatal use of EGCG in Down Syndrome
The use of EGCG from green tea has shown beneficial effects on memory and learning in clinical trials of adults with Down Syndrome. The prenatal supplementation with EGCG during the third-trimester of pregnancy may eventually help rescue the nervous system of children carrying Trisomy 21. MELISA Institute with a group of experts in fetal medicine are elaborating the first clinical protocol for prenatal use of EGCG to assess safety, tolerability, and preliminary efficacy on neurodevelopment after birth.